Repligen (RGEN) investor relations material

Executive summary

• Q2 2026 revenue reached $204 million, up 12% year-over-year (13% organic), led by strong performance in Proteins (~50% growth) and Process Analytics (>30% growth), with robust execution and broad-based demand across franchises.

• Adjusted operating income rose 55% year-over-year to $34 million, with adjusted EPS up 46% to $0.54.

• Raised full-year 2026 guidance for organic revenue growth (10.5%-13.5%) and adjusted EPS ($2.03-$2.09), reflecting increased confidence from positive order momentum and end-market recovery.

• Announced definitive agreement to acquire BioLife Solutions, expected to accelerate cell therapy strategy and be financially accretive.

• Opened a new Training & Innovation Center in the Netherlands and published the 2025 Sustainability Report.

Financial highlights

• Q2 revenue reached $204 million, up from $182 million in Q2 2025, with recurring revenue growth across the portfolio.

• Adjusted gross profit was $110 million (53.9% margin), up 280 basis points year-over-year.

• Adjusted operating income was $34 million (16.7% margin), up from $22 million year-over-year, with 460 basis points margin expansion.

• Adjusted EBITDA was $43.8 million (21.4% margin); adjusted net income was $31 million, up 45% year-over-year.

• Cash and marketable securities totaled $810 million at quarter-end, up $25 million sequentially.

Outlook and guidance

• Full-year 2026 revenue guidance raised to $813–$835 million (10–13% reported growth, 10.5–13.5% organic).

• Adjusted operating income guidance increased to $128–$134 million (15.7–16% margin), with adjusted EBITDA margin expected at 20.3%–21.0%.

• Adjusted EPS guidance raised to $2.03–$2.09, up $0.32–$0.38 from 2025.

• Q3 expected to be the lowest margin quarter, with sequential improvement in Q4.

• Guidance excludes BioLife impact, as the transaction is expected to close in Q4.